A. Pearson

发表

Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.

Ruth Ladenstein, Adela Cañete, Victoria Castel, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.

Ruth Ladenstein, Victoria Castel, A. Cañete, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intercontinental collaboration in clinical trials for children and adolescents with cancer—A systematic review by ACCELERATE

P. Kearns, G. Vassal, G. Reaman, 2021, Cancer medicine.

Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.

K. Norga, K. Wilner, Martha Donoghue, 2021, European journal of cancer.

Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results.

M. Gaze, M. Partridge, F. Saran, 2007, Cancer biotherapy & radiopharmaceuticals.

CARBOPLATIN OR CISPLATIN?

M. Stevens, I. Lewis, C. Pinkerton, 1989, The Lancet.

Rethinking high‐risk neuroblastoma treatment

S. Cohn, A. Pearson, 2022, Pediatric blood & cancer.

Evaluation of Clinically Translatable Magnetic Resonance Imaging Biomarkers of Therapeutic Response in the TH-MYCN Transgenic Mouse Model of Neuroblastoma

D. Koh, Chris Jones, Y. Jamin, 2015 .

Individualized 131I-mIBG therapy in the management of refractory and relapsed neuroblastoma

H. Mandeville, F. Saran, G. Flux, 2016, Nuclear medicine communications.

What can we expect from neuroblastoma screening? Clinicians point of view

F. Berthold, D. Frappaz, K. Matthay, 1998 .

Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study

G. Schleiermacher, T. Trahair, R. Luksch, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Additional Therapies to Improve Metastatic Response to Induction Therapy in Children With High-risk Neuroblastoma

D. Levine, A. Pearson, L. Moreno, 2015, Journal of pediatric hematology/oncology.

Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project

F. Berthold, K. Matthay, P. Ambros, 2014, Pediatric blood & cancer.

Novel therapies for children with acute myeloid leukaemia

P. Kearns, C. Zwaan, S. Knapper, 2013, Leukemia.

Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research.

D. Reinhardt, C. Zwaan, A. L. Frazier, 2021, JCO clinical cancer informatics.

Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.

Ruth Ladenstein, Jérôme Couturier, Victoria Castel, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients

A. Boddy, M. Cole, G. Veal, 2010, Cancer Chemotherapy and Pharmacology.

Childhood extracranial neoplasms: the role of imaging in drug development and clinical trials

D. Collins, D. Koh, N. Jerome, 2015, Pediatric Radiology.

Topotecan-Vincristine-Doxorubicin in Stage 4 High-Risk Neuroblastoma Patients Failing to Achieve a Complete Metastatic Response to Rapid COJEC: A SIOPEN Study

R. Haupt, R. Luksch, R. Ladenstein, 2017, Cancer research and treatment : official journal of Korean Cancer Association.

Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial - A European ITCC-SIOPEN trial

B. Morland, K. Wheatley, R. Ladenstein, 2019, Annals of Oncology.

Phase I trials in paediatric oncology — the European perspective

I. Lewis, D. Newell, A. Pearson, 2004, Investigational New Drugs.

Urinary Retention—An Unusual Dystonic Reaction to Continuous Metoclopramide Infusion

A. Craft, I. Sharkey, A. Pearson, 1991, DICP : the annals of pharmacotherapy.

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin

M. Tilby, A. Pearson, C. Austin, 2002, British Journal of Cancer.

Systematic review of clinical drug development activities for neuroblastoma from 2011 to 2020

Florence T. Bourgeois, F. Bourgeois, R. Bagatell, 2022, Pediatric blood & cancer.

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group

P. Bruzzi, B. Bernardi, Y. Rycke, 2008, British Journal of Cancer.

28 years of high-dose therapy and SCT for neuroblastoma in Europe: lessons from more than 4000 procedures

G. Dini, I. Yaniv, T. Klingebiel, 2008, Bone Marrow Transplantation.

Prospective validation of renal function-based carboplatin dosing in children with cancer: A United Kingdom Children's Cancer Study Group Trial.

A. Boddy, M. Stevens, I. Lewis, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.